These Tc were transferred into secondary AML-bearing mice after allo-HCT, resulting in improved survival in mice that received Tc from anti–TIM-3–treated recipients compared with isotype-treated mice (Figure 6A). Here, HAVCR2 is linked to acute myeloid leukemia.